Insilico Medicine has just signed a deal worth up to $2.75 billion with Eli Lilly, putting the spotlight firmly on AI-driven drug discovery.
In this episode of Companies to Watch, Dan Koh and Ryan Huang break down what Insilico Medicine actually does, why its Hong Kong IPO drew massive investor demand, and what this latest partnership means for the future of healthcare.

Ask Gurmit: Singapore's funniest man answers your questions
14:07

Singapore Icons: Gurmit Singh's journey from shift worker to Phua Chu Kang
26:38

Singapore Unfiltered: Singapore's MRT is World-Class. So why are we still complaining?
24:19